This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-15. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
IUPAC made a recommendation in 1991 for the description and measurement of carryover effects in clinical chemistry. The carryover ratio is the percentage of H3 carry to L1 constituting the carryover portion "h". In a design of 3 high samples followed by 3 low samples, h can be calculated as (L1 - mean of L2&L3) / (H3 - mean of L2&L3) The carry-over ratio's acceptance criteria depend on the measurement and the laboratory concerned. For example, 1% carryover of plasma albumin would generally lead to a clinically insignificant effect, while 1% carryover of cardiac High sensitivity Troponin assay would be catastrophic.
== Chemistry == Nordazepam is similar to diazepam, except that the methyl group at the R1 position has been replaced with a hydrogen. Nordazepam can be synthesized with 2-amino-5-chlorobenzophenone and chloroacetyl chloride. Nordazepam itself can also be used in the synthesis of diazepam by methylating the R1 position using dimethyl sulfate.
=== Venetoclax === BCL-2 is a cellular protein that can act to inhibit cell death due to apoptosis. The BCL-2 gene appears to be one of the most up-regulated (i.e. overactive) genes in BPDCN. Venetoclax inhibits the apoptosis-inhibiting action of BCL-2 and proved active in treating two patients with relapsed or refractory BPDCN. A phase I clinical trial testing the safety and efficacy of the drug in BPDCN is planned but not yet in its recruiting phase.
=== Use of unmarked aircraft === Sec. Hegseth was asked in January 2026 about a U.S. military plane that attacked a suspected drug boat in the Caribbean. The plane was not marked as a U.S. military plane and carried the armaments inside the plane, according to reports. Using unmarked aircraft in military attacks is against Defense Department policy. Pentagon press secretary Kingsley Wilson did not deny the reports, simply stating, "the U.S. military utilizes a wide array of standard and nonstandard aircraft depending on mission requirements." The Pentagon went on to state that the plane was used because it was the quickest to get ready for the operation.
More than two hundred men and women Morgan State athletes have been inducted into the Morgan State University Hall of Fame including National Football League Hall of Famers Rosey Brown, Leroy Kelly and Willie Lanier, two-time Olympic Gold medalist George Rhoden, and the coach of the Ten Bears lacrosse team Howard "Chip" Silverman.
Sources: en.wikipedia.org
Nucleic acids (including RNA and DNA) are nucleotide polymers synthesized by polymerase enzymes during either transcription or DNA replication. Following 5'-3' synthesis of the backbone, individual nitrogenous bases are capable of interacting with one another via hydrogen bonding, thus allowing for the formation of higher-order structures. Nucleic acid denaturation occurs when hydrogen bonding between nucleotides is disrupted, and results in the separation of previously annealed strands. For example, denaturation of DNA due to high temperatures results in the disruption of base pairs and the separation of the double stranded helix into two single strands. Nucleic acid strands are capable of re-annealling when "normal" conditions are restored, but if restoration occurs too quickly, the nucleic acid strands may re-anneal imperfectly resulting in the improper pairing of bases.
Manufacture of the drug was discontinued for several months beginning in late 2011; however, production and distribution resumed in 2012, so the drug is still available in the United States by prescription. Thus, it is unclear as to whether the lapse in manufacture actually resulted in a shortage of the drug at any time, since prescription drugs are often still available for many months after manufacture has been discontinued. In France, paregoric was available without prescription until 1986; nowadays, it is used to wean infants born to opiate-addicted women.
LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1): LRP1 is involved in the endocytosis and degradation of various ligands, including AGEs. It is expressed in tissues such as the liver, vascular smooth muscle cells, and neurons. LRP1 functions by promoting the cellular uptake of AGE-modified proteins, thereby preventing their accumulation and reducing oxidative damage. The receptor also interacts with signaling pathways that regulate inflammation, making it an important factor in protecting against AGE-induced vascular and metabolic complications. MSR1 (Macrophage Scavenger Receptor 1): MSR1, also known as class A scavenger receptor, is expressed primarily on macrophages and plays a crucial role in the phagocytic uptake of AGEs. By recognizing and internalizing AGE-modified proteins, MSR1 helps reduce inflammation and cellular stress in tissues exposed to AGEs. This receptor is involved in activating pro-inflammatory signaling pathways, but it also contributes to tissue repair and the resolution of inflammation, helping maintain tissue homeostasis. FEEL-1/CLEC14A (Facultative Endothelial Lectin-1): FEEL-1, also known as CLEC14A, is a C-type lectin receptor expressed on endothelial cells. It binds AGEs and facilitates their clearance, thereby helping to maintain vascular health. The interaction of FEEL-1 with AGEs is thought to reduce endothelial cell activation and inflammation, contributing to the protection of blood vessels from AGE-induced damage and maintaining vascular integrity.
== Early life == Morgan was born on November 10, 1968, in Brooklyn and raised in Brooklyn's Marlboro Houses and Tompkins Houses in its Bedford–Stuyvesant neighborhood. He is the second of five children of a homemaker, Alicia (née Warden), and James Morgan Jr IV, a musician who left the family when Morgan was six years old. His father named him Tracy in honor of a platoon mate and friend who shipped off to Vietnam with him and was killed in action days later. The target of bullies as a child, Morgan attended DeWitt Clinton High School in The Bronx. In 1985, during his senior year, he learned that his father had contracted HIV from hypodermic needle use. His father died in January 1987, aged 38. Morgan married his girlfriend Sabina that year and dropped out of high school just four credits short of his diploma to care for his ailing father. Living on welfare, Morgan sold crack cocaine with limited success, but began earning money performing comedy on the streets after his best friend was murdered. He said in 2009: "He would say to me, 'Yo, Tracy, man, you should be doing comedy.' A week later, he was murdered. And that for me, that was like my Vietnam. I had my survival guilt when I started to achieve success. Why I made it out and some guys didn't." Morgan embarked on a stand-up comedy career, successfully enough that he "finally moved to a nice community in [The Bronx neighborhood of] Riverdale, from a run-down apartment next to Yankee Stadium in the Bronx."
Sources: en.wikipedia.org
The duration of the folding process varies dramatically depending on the protein of interest. When studied outside the cell, the slowest folding proteins require many minutes or hours to fold, primarily due to proline isomerization, and must pass through a number of intermediate states, like checkpoints, before the process is complete. On the other hand, very small single-domain proteins with lengths of up to a hundred amino acids typically fold in a single step. Time scales of milliseconds are the norm, and the fastest known protein folding reactions are complete within a few microseconds. The folding time scale of a protein depends on its size, contact order, and circuit topology. Understanding and simulating the protein folding process has been an important challenge for computational biology since the late 1960s.
Insulin may not be necessary and it may be possible to switch a person from insulin injections to oral agents without loss of glycemic control. It may prompt screening of relatives and so help identify other cases in family members. As it occurs infrequently, many cases of MODY are initially assumed to be more common forms of diabetes: type 1 if the patient is young and not overweight, type 2 if the patient is overweight, or gestational diabetes if the patient is pregnant. Standard diabetes treatments (insulin for type 1 and gestational diabetes, and oral hypoglycemic agents for type 2) are often initiated before the doctor suspects a more unusual form of diabetes.
Some cats will have completed the shedding period by the time the test is run, leading to false-negative results. Electron microscopy, virus isolation and seroconversion can also be used to document active or recent infection. Leukopenia on a complete blood count (nadir 50–3,000 WBC/μL) supports a diagnosis of FPLV. In an unvaccinated cat, the presence of antibodies against FPV indicates that the cat either has the disease or has had the disease in the past. Elevated IgM titers (1:10 or greater) indicate active infection and if clinical signs are obvious (diarrhea, panleukopenia) the prognosis is poor. Elevated IgG titers (1:100 or greater) in a cat with clinical signs indicates a better prognosis. Differential diagnoses include salmonellosis, enteric toxins, feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), cryptosporidiosis, pancreatitis, septicaemia with acute endotoxemia, toxoplasmosis, peritonitis, and lymphoma.
The α-globin chains are encoded by two closely linked genes HBA1 and HBA2 on chromosome 16; in a person with two copies on each chromosome, a total of four loci encode the α chain. Two alleles are maternal and two alleles are paternal in origin. Alpha-thalassemias result in decreased alpha-globin production, resulting in an excess of β chains in adults and excess γ chains in fetus and newborns.
In 1957, Boyd Orr served as president of the Second International Humanist Congress, and contributed to the 1968 volume The Humanist Outlook alongside many other prominent humanists. In 1960 Boyd Orr was elected the first president of the World Academy of Art and Science, which was set up by eminent scientists of the day concerned about the potential misuse of scientific discoveries, most especially nuclear weapons. Along with Albert Einstein, Orr was one of the sponsors of the Peoples' World Convention (PWC), also known as Peoples' World Constituent Assembly (PWCA), which took place in 1950–51 at Palais Electoral, Geneva, Switzerland. He was also one of the signatories of the agreement to convene a convention for drafting a world constitution. As a result, for the first time in human history, a World Constituent Assembly convened to draft and adopt the Constitution for the Federation of Earth. Boyd Orr was a member of Bertrand Russell's Who Killed Kennedy? Committee which challenged the official version of the assassination of John F. Kennedy.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.